An open label, randomized control study for the comparison of effectiveness between Alfa-Glucosidase inhibitor and Dipeptidyl peptidase-4 (DPP-4) inhibitor in people with type 2 diabetes treated diet therapy and/or single oral hypoglycemic agent

An open label, randomized control study for the comparison of effectiveness between Alfa-Glucosidase inhibitor and Dipeptidyl peptidase-4 (DPP-4) inhibitor in people with type 2 diabetes treated diet therapy and/or single oral hypoglycemic agent - An open label, randomized control study for the comparison of effectiveness between Alfa-Glucosidase inhibitor and Dipeptidyl peptidase-4 (DPP-4) inhibitor in people with type 2 diabetes treated diet therapy and/or single oral hypoglycemic agent

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003503

Enrollment

260

Registered

2010-04-21

Start date

2010-05-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

sitagliptin 50mg once a day for 12 weeks. However for mild renal failure, once-daily sitagliptin 25mg for 12 weeks voglibose 0.2mg three times a day, at the start of each main meal

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Type 2 diabetes 2)HbA1c >=6.5% during 8 weeks prior to the study 3)Treated with none or single oral hypoglycemic agent(OHA:SU,BG,TZD) over 12 weeks prior to the study

Exclusion criteria

Exclusion criteria: 1.None Type 2 diabetes 2.Medical history and/or complication of diabetic ketoacidosis 3.Medical history and/or complication of severe hypoglycemia 4.Insulin treatment within 16 weeks prior to the study 5.Treatment with Alfa-glucosidase inhibitors or sitagliptin within 12 weeks prior to the study 6.Treatment with glucocorticoid 7.Unstable glycemic contol 8.Hypersensitivity to or contraindication of sitagliptin and voglibose 9.AST or ALT >=2.5 time of institutional upper normal limit 10.Uncontrolled hypertension(systolic blood pressure >160mmHg or diastolic blood pressure >100mmHg) 11.Severe health problems not suitable for the study 12.Pregnant or lactating women

Design outcomes

Primary

Measure	Time frame
HbA1C	—

Countries

Japan

Contacts

Public ContactYumie Takeshita

Kanazawa University Graduate School of Medical Science Department of Disease Control and Homeostasis

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026